Unlabelled: Oral cancer (OC) is one of the global diseases that is the eighth rank among different others. Early intervention therapy had a positive impact on increasing the prognosis and the survival rate up to 5 years. The aim of the current study was to evaluate the knowledge, attitude, and practice of dentists about OC in the Democratic Republic of the Congo (DRC).
Materiel And Methods: It was a cross-sectional analytical survey conducted in the primary oral health care centers in DR. Congo from February to April 2021. Only dentists working at any of the primary oral health care centers, public or private was included. Data were collected by using a survey of a 33-item questionnaire. The practice level, knowledge, risk factors, diagnosis for OC, attitude, and opinions of the dentists were recorded and evaluated. The SPSS 20 was used for data analysis and P < 0.05 was considered significant.
Results: Out of 162 dentists recorded, 65.4% were male and 34.6% were females. Half of the dentists (50.6%) had more than 5-15 years of practical experience, and 81.5% of the participants were general practice dentists. A majority of dentists were not familiar with the proper physical oral examination steps (80.2%). The practice level of the dentists was highly poor. The knowledge level about clinical features and diagnostic procedures (frequent anatomical region, common type of OC, associated factor with OC, frequent stage diagnosis of OC, and condition associated with OC) was very low. The dentists' gender was associated with a poor level of practice (P = 0.009). However, the age experience of work was associated with the high knowledge of the clinical presentation of oral cancer (P = 0.040).
Conclusion: The dentists in DRC have obvious problems in the knowledge of OC diagnosis. More continued education and training programs for dentists would serve to address the knowledge deficits and practice shortcomings about oral cancer screening, prevention, and early detection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jcpo.2022.100332 | DOI Listing |
Adv Clin Exp Med
January 2025
Department of Dermatology, The Affiliated Hospital to Changchun University of Chinese Medicine, China.
Background: The skin, with its robust structural integrity and advanced immune defense system, serves as a critical protective barrier against environmental toxins and carcinogenic compounds. Despite this, it remains vulnerable to the harmful effects of certain hazardous agents.
Objectives: This study aimed to investigate the chemopreventive potential of β-caryophyllene (BCP) in mitigating 7,12-dimethylbenz[a]anthracene (DMBA)-induced skin carcinogenesis, focusing on the modulation of apoptosis and PI3K/AKT signaling pathways.
Head Neck
January 2025
Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Background: Radiotherapy (RT) in head and neck cancer (HNC) can cause multiple side effects such as nausea, pain, taste loss, fatigue, oral mucositis, xerostomia, and acute radiation-associated dysphagia (RAD). These factors threaten patients' oral intake (OI) during this RT. Reduced OI can cause weight loss, dehydration, malnutrition, and various comorbidities.
View Article and Find Full Text PDFJAMA Netw Open
January 2025
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Importance: The D842V platelet-derived growth factor receptor α (PDGFRA) mutation identifies a molecular subgroup of gastrointestinal stromal tumors (GISTs), primarily resistant to standard tyrosine kinase inhibitors and with an overall more indolent behavior. Although functional imaging with 18F-fluorodeoxyglucose-labeled positron emission tomography ([18F]FDG-PET) plays a proven role in GISTs, especially in early assessment of tumor response, less is known about [18F]FDG uptake according to the GIST molecular subtypes.
Objective: To evaluate the degree of [18F]FDG uptake in PDGFRA-mutant GISTs and better define the role of functional imaging in this rare and peculiar subset of GISTs.
Cancer
February 2025
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Background: Talabostat, an oral small molecule inhibitor of dipeptidyl peptidases (DPP4 and DPP8/9), has shown synergistic activity with immune checkpoint inhibitors in preclinical studies. This open label, phase 2 basket trial assessed the antitumor activity of combining talabostat and pembrolizumab (anti-programmed death-1 antibody) in advanced solid tumor patients.
Methods: The primary objective was assessment of dose-limiting toxicity (DLT) rates in the first six patients (lead-in stage) and response rate (efficacy stage; included cohort A [checkpoint inhibitor (ICI) naive] and cohort B [ICI pretreated]) for the study treatment using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.
J Funct Biomater
January 2025
Hospital of Stomatology, Guanghua School of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou 510055, China.
Oral diseases such as dental caries, periodontitis, and oral cancer are prevalent and present significant challenges to global public health. Although these diseases are typically treated through procedures like dental preparation and resin filling, scaling and root planning, or surgical excision, these interventions are often not entirely effective, and postoperative drug therapy is usually required. Traditional drug treatments, however, are limited by factors such as poor drug penetration, significant side effects, and the development of drug resistance.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!